Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | APAF1 | O14727 | 2/20 | 0.35 |
| ▸ | UBE2N | P61088 | 2/20 | 0.35 |
| ▸ | IDE | P14735 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623671 | 0.82 | APAF1 (0.34) | GPBAR1TACR1APAF1UBE2NIDE | |
| SCHEMBL5623686 | 0.82 | TACR1 (0.40) | GPBAR1TACR1APAF1UBE2NIDE | |
| SCHEMBL5628380 | 0.82 | TACR1 (0.33) | GPBAR1TACR1APAF1UBE2NIDE | |
| SCHEMBL5627070 | 0.80 | TACR1 (0.40) | GPBAR1TACR1CCR2 | |
| SCHEMBL5623804 | 0.78 | TACR1 (0.31) | GPBAR1TACR1 | |
| SCHEMBL4228529 | 0.78 | GRM2 (0.36) | APAF1UBE2NIDERECQLNPSR1 | |
| SCHEMBL4222356 | 0.78 | APAF1 (0.33) | APAF1UBE2NIDERECQLNPSR1 | |
| SCHEMBL5624607 | 0.78 | BCDIN3D (0.33) | TACR1APAF1UBE2NIDERECQL | |
| SCHEMBL5623662 | 0.77 | TACR1 (0.41) | GPBAR1TACR1CCR2 | |
| SCHEMBL5046166 | 0.77 | DRD4 (0.40) | GPBAR1TACR1IDECCR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | SAKAKI JUNICHI | 2009-03-19 | — | — | US | disclosed |
| EP-1968941-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007073934-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | CETP, PCSK9, MTTP | GPBAR1 443/4885TACR1 1092/4885APAF1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.